Nasdaq
$2.89▼ 2.69%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.9MShares out 1.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
24- 10.8Pre-market26.10.08 19:056-KKey event#●●●#●●●#●●●
Addex Therapeutics Ltd.Bullish
Neurosterix, a spin-out company in which Addex Therapeutics holds a 20% equity interest, has completed Phase 1 clinical studies for its schizophrenia drug candidate, NTX-253. Based on the safety and pharmacokinetic data obtained, Neurosterix plans to advance NTX-253 into Phase 2 clinical development.…more
$2.89-2.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2Pre-market26.10.02 19:056-KKey event
Addex Therapeutics Ltd.
Addex Therapeutics has appointed Jean-Philippe Rocher as Head of Pharmaceutical Development, succeeding Mikhail Kalinichev, who is stepping down to focus on his role at Neurosterix. Dr. Rocher, a former Addex executive, returns to lead the company's clinical development pipeline and chemistry platform initiatives.…more
$2.89-2.69%vs prev closeView filingShare - 9.28Pre-market26.09.28 20:066-KKey event
Addex Therapeutics Ltd.
Addex Therapeutics reported its 2026 half-year financial results and announced the successful raising of 2.8 million USD (2.3 million CHF) through an ATM offering between July 1 and August 25, 2026. The company also regained all rights to its GABAB PAM program following the termination of its license agreement with Indivior and plans to seek further funding to advance its clinical development programs.…more
$2.89-2.69%vs prev closeView filingShare
23 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.8Overnight26.10.08 14:00#●●●#●●●#●●●
Addex Spin-out Neurosterix Completes Phase 1 Trial for Schizophrenia Drug…more
Neurosterix, an affiliate of Addex Therapeutics, has completed Phase 1 clinical studies for its schizophrenia candidate NTX-253. The company plans to advance the program into Phase 2, though the development remains in early clinical stages.…more
$2.89-2.69%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.2Overnight26.10.02 14:00
●●●●●●●● ●●●●● ●●●●●●
Addex Therapeutics has appointed Jean-Philippe Rocher as the new Head of Pharmaceutical Development. Meanwhile, Mikhail Kalinichev is stepping down from his role to focus on his position at the spin-out company, Neurosterix.…more
$2.89-2.69%vs prev close - 9.28Regular26.09.28 23:10
●●●●●●●● ●●●●● ●●●●●●
Addex Therapeutics reported Q2 revenue of $12,650, marking a 71.27% decrease compared to the same period last year. While the loss per share improved slightly, the company continues to face significant financial challenges.…more
$2.89-2.69%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report